Hereditary Cancer Clinics Improve Adherence to NCCN Germline Testing Guidelines for Pancreatic Cancer
Journal of the National Comprehensive Cancer Network · 2024
DOI: 10.6004/jnccn.2023.7333 ↗Kurz gefasst
Leitlinie in der Zeitschrift Journal of the National Comprehensive Cancer Network, 2024. Verfasst von Claudia Rosso und 11 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, University of California, Irvine, Irvine, CA. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Genetic Testing, Guideline Adherence, Germ-Line Mutation. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Background
Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis, with a 5-year overall survival rate of 10%. In November 2018, NCCN recommended that all patients with PDAC receive genetic counseling (GC) and germline testing regardless of family history. We hypothesized that patients with PDAC were more likely to be referred for testing after this change to the guidelines, regardless of presumed predictive factors, and that compliance would be further improved following the implementation of a hereditary cancer clinic (HCC).
Methods
We conducted a single-institution retrospective analysis of patients diagnosed with PDAC from June 2017 through December 2021 at University of California, Irvine. We compared rates of genetics referral among patients in different diagnostic eras: the 18-month period before the NCCN Guideline change (pre-NCCN era: June 2017 through November 2018), 14 months following the change (post-NCCN era: December 2018 through January 2020), and 18 months after the creation of an HCC (HCC era: June 2020 through December 2021). Family and personal cancer history, genetics referral patterns, and results of GC were recorded. Data were compared using chi-square, Fisher exact, and multivariate analyses.
Results
A total of 335 patients were treated for PDAC (123 pre-NCCN, 109 post-NCCN, and 103 HCC) at University of California, Irvine. Demographics across groups were comparable. Prior to the guideline changes, 30% were referred to GC compared with 54.7% in the post-NCCN era. After the implementation of the HCC, 77.4% were referred to GC ( P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- School of Medicine, University of California, Irvine, Irvine, CA.
- Division of Genetic and Genomic Medicine, Department of Pediatrics, University of California, Irvine, Irvine, CA.
- Chao Family Comprehensive Cancer Center, University of California, Irvine, Irvine, CA.
- Division of Hematology/Oncology, Department of Medicine, UCI School of Medicine, Irvine, CA.
Förderung
- NCI NIH HHS
Zitieren
APA
Rosso, C., Marciano, N. D., Nathan, D., Chen, W. P., McLaren, C. E., Osann, K. E., Flodman, P. L., Cho, M. T., Lee, F. C., Dayyani, F., Zell, J. A., & Valerin, J. B. (2024). Hereditary Cancer Clinics Improve Adherence to NCCN Germline Testing Guidelines for Pancreatic Cancer. Journal of the National Comprehensive Cancer Network. https://doi.org/10.6004/jnccn.2023.7333
Vancouver
Rosso C, Marciano ND, Nathan D, Chen WP, McLaren CE, Osann KE, et al. Hereditary Cancer Clinics Improve Adherence to NCCN Germline Testing Guidelines for Pancreatic Cancer. Journal of the National Comprehensive Cancer Network. 2024. doi:10.6004/jnccn.2023.7333
BibTeX
@article{Rosso2024,
author = {Rosso, Claudia and Marciano, Naomie Devico and Nathan, Deepika and Chen, Wen-Pin and McLaren, Christine E and Osann, Kathryn E and Flodman, Pamela L and Cho, May T and Lee, Fa-Chyi and Dayyani, Farshid and Zell, Jason A and Valerin, Jennifer B},
title = {Hereditary Cancer Clinics Improve Adherence to NCCN Germline Testing Guidelines for Pancreatic Cancer},
journal = {Journal of the National Comprehensive Cancer Network},
year = {2024},
doi = {10.6004/jnccn.2023.7333}
}
EUVIMED